ID   GIST-T1
AC   CVCL_4976
SY   GIST-T-1; GISTT1; T1
DR   ChEMBL-Cells; CHEMBL4482986
DR   ChEMBL-Targets; CHEMBL4483238
DR   Cosmic; 1029465
DR   Cosmic; 1873953
DR   Cosmic; 2607430
DR   Cosmic; 2805388
DR   DepMap; ACH-002332
DR   GEO; GSM1701539
DR   GEO; GSM2527248
DR   GEO; GSM2527250
DR   GEO; GSM2527251
DR   GEO; GSM2527316
DR   GEO; GSM2527317
DR   GEO; GSM2527318
DR   GEO; GSM2527319
DR   GEO; GSM3070588
DR   PubChem_Cell_line; CVCL_4976
DR   Wikidata; Q54835846
RX   PubMed=12004007;
RX   PubMed=16077968;
RX   PubMed=19706776;
RX   PubMed=22665524;
RX   PubMed=23716303;
RX   PubMed=25239608;
RX   PubMed=27997714;
RX   PubMed=29866822;
RX   PubMed=32736695;
RX   PubMed=34738628;
WW   https://www.cosmobio.com/contents/gist-t1_culture_kit.html
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Japanese.
CC   Doubling time: 48 hours (PubMed=12004007).
CC   Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Tyr578del (c.1679_1735del); Zygosity=Heterozygous (PubMed=12004007; PubMed=16077968).
CC   Omics: Chromatin accessibility by ATAC-seq.
CC   Omics: Deep exome analysis.
CC   Omics: Deep tyrosine phosphoproteome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
CC   Cell type: Interstitial cell of Cajal; CL=CL_0002088.
DI   NCIt; C3868; Gastrointestinal stromal tumor
DI   ORDO; Orphanet_44890; Gastrointestinal stromal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 17
//
RX   PubMed=12004007; DOI=10.1038/labinvest.3780461;
RA   Taguchi T., Sonobe H., Toyonaga S.-i., Yamasaki I., Shuin T.,
RA   Takano A., Araki K., Akimaru K., Yuri K.;
RT   "Conventional and molecular cytogenetic characterization of a new
RT   human cell line, GIST-T1, established from gastrointestinal stromal
RT   tumor.";
RL   Lab. Invest. 82:663-665(2002).
//
RX   PubMed=16077968; DOI=10.3892/or.14.3.645;
RA   Noma K., Naomoto Y., Gunduz M., Matsuoka J., Yamatsuji T.,
RA   Shirakawa Y., Nobuhisa T., Okawa T., Takaoka M., Tomono Y.,
RA   Hiroyuki O., Gunduz E., Tanaka N.;
RT   "Effects of imatinib vary with the types of KIT-mutation in
RT   gastrointestinal stromal tumor cell lines.";
RL   Oncol. Rep. 14:645-650(2005).
//
RX   PubMed=19706776; DOI=10.1158/0008-5472.CAN-08-4004;
RA   Muhlenberg T., Zhang Y.-X., Wagner A.J., Grabellus F., Bradner J.,
RA   Taeger G., Lang H., Taguchi T., Schuler M., Fletcher J.A., Bauer S.;
RT   "Inhibitors of deacetylases suppress oncogenic KIT signaling,
RT   acetylate HSP90, and induce apoptosis in gastrointestinal stromal
RT   tumors.";
RL   Cancer Res. 69:6941-6950(2009).
//
RX   PubMed=22665524; DOI=10.1158/1535-7163.MCT-12-0223;
RA   Heinrich M.C., Marino-Enriquez A., Presnell A., Donsky R.S.,
RA   Griffith D.J., McKinley A., Patterson J., Taguchi T., Liang C.-W.,
RA   Fletcher J.A.;
RT   "Sorafenib inhibits many kinase mutations associated with
RT   drug-resistant gastrointestinal stromal tumors.";
RL   Mol. Cancer Ther. 11:1770-1780(2012).
//
RX   PubMed=23716303; DOI=10.1002/ijc.28282;
RA   Takahashi T., Serada S., Ako M., Fujimoto M., Miyazaki Y.,
RA   Nakatsuka R., Ikezoe T., Yokoyama A., Taguchi T., Shimada K.,
RA   Kurokawa Y., Yamasaki M., Miyata H., Nakajima K., Takiguchi S.,
RA   Mori M., Doki Y., Naka T., Nishida T.;
RT   "New findings of kinase switching in gastrointestinal stromal tumor
RT   under imatinib using phosphoproteomic analysis.";
RL   Int. J. Cancer 133:2737-2743(2013).
//
RX   PubMed=25239608; DOI=10.1158/1078-0432.CCR-14-1397;
RA   Garner A.P., Gozgit J.M., Anjum R., Vodala S., Schrock A.B., Zhou T.-J.,
RA   Serrano C., Eilers G., Zhu M.-J., Ketzer J., Wardwell S., Ning Y.,
RA   Song Y., Kohlmann A., Wang F., Clackson T., Heinrich M.C.,
RA   Fletcher J.A., Bauer S., Rivera V.M.;
RT   "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and
RT   shows therapeutic potential in heavily pretreated gastrointestinal
RT   stromal tumor (GIST) patients.";
RL   Clin. Cancer Res. 20:5745-5755(2014).
//
RX   PubMed=27997714; DOI=10.1002/gcc.22438;
RA   Takahashi T., Elzawahry A., Mimaki S., Furukawa E., Nakatsuka R.,
RA   Nakamura H., Nishigaki T., Serada S., Naka T., Hirota S., Shibata T.,
RA   Tsuchihara K., Nishida T., Kato M.;
RT   "Genomic and transcriptomic analysis of imatinib resistance in
RT   gastrointestinal stromal tumors.";
RL   Genes Chromosomes Cancer 56:303-313(2017).
//
RX   PubMed=29866822; DOI=10.1073/pnas.1802079115;
RA   Hemming M.L., Lawlor M.A., Zeid R., Lesluyes T., Fletcher J.A.,
RA   Raut C.P., Sicinska E.T., Chibon F., Armstrong S.A., Demetri G.D.,
RA   Bradner J.E.;
RT   "Gastrointestinal stromal tumor enhancers support a transcription
RT   factor network predictive of clinical outcome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:E5746-E5755(2018).
//
RX   PubMed=32736695; DOI=10.1016/j.bbrc.2020.05.174;
RA   Cho W.-C., Shin Y.-K., Na Y.-S., Ryu M.-H., Ku J.-L., Kang Y.-K.;
RT   "The role of novel fusion genes in human GIST cell lines derived from
RT   imatinib-resistant GIST patients: a therapeutic potential of fusion
RT   gene.";
RL   Biochem. Biophys. Res. Commun. 529:699-706(2020).
//
RX   PubMed=34738628; DOI=10.3892/or.2021.8218;
RA   Shima T., Taniguchi K., Tokumaru Y., Inomata Y., Arima J., Lee S.-W.,
RA   Takabe K., Yoshida K., Uchiyama K.;
RT   "Glucose transporter-1 inhibition overcomes imatinib resistance in
RT   gastrointestinal stromal tumor cells.";
RL   Oncol. Rep. 47:7.1-7.13(2022).
//